{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:50:42Z","timestamp":1788922242829,"version":"build-2803163510"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12035-024-04569-8","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T16:02:59Z","timestamp":1730131379000},"page":"4520-4532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Vilazodone,\u00a0a\u00a0Novel SSRI Antidepressant with 5-HT1A Partial Agonist Properties: Diminished Potentiation of Chronic Oral Methylphenidate-Induced Dynorphin Expression in the Striatum in Adolescent Male Rats"],"prefix":"10.1007","volume":"62","author":[{"given":"Michael","family":"Hrabak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle G.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayotis K.","family":"Thanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"4569_CR1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1087054707299597","volume":"10","author":"L Castle","year":"2007","unstructured":"Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS (2007) Trends in medication treatment for ADHD. J Atten Disord 10:335\u2013342","journal-title":"J Atten Disord"},{"key":"4569_CR2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/1087054707311654","volume":"12","author":"SH Kollins","year":"2008","unstructured":"Kollins SH (2008) ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J Atten Disord 12:115\u2013125","journal-title":"J Atten Disord"},{"key":"4569_CR3","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1037\/a0024898","volume":"137","author":"JM Swanson","year":"2011","unstructured":"Swanson JM, Wigal TL, Volkow ND (2011) Contrast of medical and nonmedical use of stimulant drugs, basis for the distinction, and risk of addiction: comment on Smith and Farah (2011). Psychol Bull 137:742\u2013748","journal-title":"Psychol Bull"},{"key":"4569_CR4","unstructured":"DSMMD (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Arlington, VA"},{"key":"4569_CR5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/archpedi.155.5.560","volume":"155","author":"JL Rushton","year":"2001","unstructured":"Rushton JL, Whitmire JT (2001) Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998. Arch Pediatr Adolesc Med 155:560\u2013565","journal-title":"Arch Pediatr Adolesc Med"},{"key":"4569_CR6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1176\/appi.ajp.160.3.438","volume":"160","author":"DJ Safer","year":"2003","unstructured":"Safer DJ, Zito JM, DosReis S (2003) Concomitant psychotropic medication for youths. Am J Psychiatry 160:438\u2013449","journal-title":"Am J Psychiatry"},{"key":"4569_CR7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00008480-200310000-00006","volume":"15","author":"J Waxmonsky","year":"2003","unstructured":"Waxmonsky J (2003) Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness. Curr Opin Pediatr 15:476\u2013482","journal-title":"Curr Opin Pediatr"},{"key":"4569_CR8","first-page":"27","volume":"8","author":"TJ Spencer","year":"2006","unstructured":"Spencer TJ (2006) ADHD and comorbidity in childhood. J Clin Psychiatry 67 Suppl 8:27\u201331","journal-title":"J Clin Psychiatry 67 Suppl"},{"key":"4569_CR9","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.4088\/JCP.v64n1202","volume":"64","author":"H Lavretsky","year":"2003","unstructured":"Lavretsky H, Kim MD, Kumar A, Reynolds CF (2003) Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J Clin Psychiatry 64:1410\u20131414","journal-title":"J Clin Psychiatry"},{"key":"4569_CR10","first-page":"6","volume":"22","author":"JC Nelson","year":"2007","unstructured":"Nelson JC (2007) Augmentation strategies in the treatment of major depressive disorder. Recent findings and current status of augmentation strategies. CNS Spectr 12 Suppl 22:6\u20139","journal-title":"CNS Spectr 12 Suppl"},{"key":"4569_CR11","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1440-1819.2008.01767.x","volume":"62","author":"M Ishii","year":"2008","unstructured":"Ishii M, Tatsuzawa Y, Yoshino A, Nomura S (2008) Serotonin syndrome induced by augmentation of SSRI with methylphenidate. Psychiatry Clin Neurosci 62:246","journal-title":"Psychiatry Clin Neurosci"},{"key":"4569_CR12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4088\/JCP.v69n0112","volume":"69","author":"AV Ravindran","year":"2008","unstructured":"Ravindran AV, Kennedy SH, O\u2019Donovan MC, Fallu A, Camacho F, Binder CE (2008) Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 69:87\u201394","journal-title":"J Clin Psychiatry"},{"key":"4569_CR13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1743-6109.2007.00630.x","volume":"5","author":"A Csoka","year":"2008","unstructured":"Csoka A, Bahrick A, Mehtonen OP (2008) Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. J Sex Med 5:227\u2013233","journal-title":"J Sex Med"},{"key":"4569_CR14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s10567-014-0177-z","volume":"18","author":"K Benson","year":"2015","unstructured":"Benson K, Flory K, Humphreys KL, Lee SS (2015) Misuse of stimulant medication among college students: a comprehensive review and meta-analysis. Clin Child Fam Psychol Rev 18:50\u201376","journal-title":"Clin Child Fam Psychol Rev"},{"key":"4569_CR15","unstructured":"SAMHSA (2015) Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. NSDUH Series H-50, HHS Publication No (SMA) 15-4927.\u00a0https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUH-FRR1-2014\/NSDUH-FRR1-2014.pdf. Accessed\u00a024 Oct 2024"},{"key":"4569_CR16","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1176\/appi.ajp.2018.17091048","volume":"175","author":"WM Compton","year":"2018","unstructured":"Compton WM, Han B, Blanco C, Johnson K, Jones CM (2018) Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the United States. Am J Psychiatry 175:741\u2013755","journal-title":"Am J Psychiatry"},{"issue":"Suppl 1","key":"4569_CR17","first-page":"S82","volume":"147","author":"L Iversen","year":"2006","unstructured":"Iversen L (2006) Neurotransmitter transporters and their impact on the development of psychopharmacology. Br J Pharmacol 147(Suppl 1):S82\u201388","journal-title":"Br J Pharmacol"},{"key":"4569_CR18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neuropharm.2004.06.021","volume":"47","author":"WAJ Carlezon","year":"2004","unstructured":"Carlezon WAJ, Konradi C (2004) Understanding the neurobiological consequences of early exposure to psychotropic drugs: linking behavior with molecules. Neuropharmacology 47:47\u201360","journal-title":"Neuropharmacology"},{"key":"4569_CR19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12264-011-1004-x","volume":"27","author":"N Carrey","year":"2011","unstructured":"Carrey N, Wilkinson M (2011) A review of psychostimulant-induced neuroadaptation in developing animals. Neurosci Bull 27:197\u2013214","journal-title":"Neurosci Bull"},{"key":"4569_CR20","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.neubiorev.2011.02.011","volume":"35","author":"EM Marco","year":"2011","unstructured":"Marco EM, Adriani W, Ruocco LA, Canese R, Sadile AG, Laviola G (2011) Neurobehavioral adaptations to methylphenidate: the issue of early adolescent exposure. Neurosci Biobehav Rev 35:1722\u20131739","journal-title":"Neurosci Biobehav Rev"},{"key":"4569_CR21","unstructured":"Van Waes V, Steiner H (2015) Fluoxetine and other SSRI antidepressants potentiate addiction-related gene regulation by psychostimulant medications. In: Pinna G (ed) Fluoxetine: pharmacology, mechanisms of action and potential side effects. Nova Science, Hauppauge, NY, pp 207\u2013225"},{"key":"4569_CR22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1196\/annals.1369.005","volume":"1074","author":"W Adriani","year":"2006","unstructured":"Adriani W, Leo D, Guarino M, Natoli A, Di Consiglio E, De Angelis G, Traina E, Testai E, Perrone-Capano C, Laviola G (2006) Short-term effects of adolescent methylphenidate exposure on brain striatal gene expression and sexual\/endocrine parameters in male rats. Ann N Y Acad Sci 1074:52\u201373","journal-title":"Ann N Y Acad Sci"},{"key":"4569_CR23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pneurobio.2012.10.001","volume":"100","author":"H Steiner","year":"2013","unstructured":"Steiner H, Van Waes V (2013) Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants. Prog Neurobiol 100:60\u201380","journal-title":"Prog Neurobiol"},{"key":"4569_CR24","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1523\/JNEUROSCI.18-14-05301.1998","volume":"18","author":"JD Berke","year":"1998","unstructured":"Berke JD, Paletzki RF, Aronson GJ, Hyman SE, Gerfen CR (1998) A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci 18:5301\u20135310","journal-title":"J Neurosci"},{"key":"4569_CR25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/13556210412331308976","volume":"10","author":"V Yuferov","year":"2005","unstructured":"Yuferov V, Nielsen D, Butelman E, Kreek MJ (2005) Microarray studies of psychostimulant-induced changes in gene expression. Addict Biol 10:101\u2013118","journal-title":"Addict Biol"},{"key":"4569_CR26","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.cell.2008.10.028","volume":"135","author":"M Heiman","year":"2008","unstructured":"Heiman M, Schaefer A, Gong S, Peterson JD, Day M, Ramsey KE, Su\u00e1rez-Fari\u00f1as M, Schwarz C, Stephan DA, Surmeier DJ, Greengard P, Heintz N (2008) A translational profiling approach for the molecular characterization of CNS cell types. Cell 135:738\u2013748","journal-title":"Cell"},{"key":"4569_CR27","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.tips.2007.10.004","volume":"28","author":"M Yano","year":"2007","unstructured":"Yano M, Steiner H (2007) Methylphenidate and cocaine: the same effects on gene regulation? Trends Pharmacol Sci 28:588\u2013596","journal-title":"Trends Pharmacol Sci"},{"key":"4569_CR28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/syn.10038","volume":"43","author":"ND Volkow","year":"2002","unstructured":"Volkow ND, Wang GJ, Fowler JS, Logan J, Franceschi D, Maynard L, Ding YS, Gatley SJ, Gifford A, Zhu W, Swanson JM (2002) Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 43:181\u2013187","journal-title":"Synapse"},{"key":"4569_CR29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neuroscience.2006.02.017","volume":"140","author":"M Yano","year":"2006","unstructured":"Yano M, Beverley JA, Steiner H (2006) Inhibition of methylphenidate-induced gene expression in the striatum by local blockade of D1 dopamine receptors: interhemispheric effects. Neuroscience 140:699\u2013709","journal-title":"Neuroscience"},{"key":"4569_CR30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1471-4159.2011.07215.x","volume":"117","author":"ME Alburges","year":"2011","unstructured":"Alburges ME, Hoonakker AJ, Horner KA, Fleckenstein AE, Hanson GR (2011) Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment. J Neurochem 117:470\u2013478","journal-title":"J Neurochem"},{"key":"4569_CR31","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.2174\/1381612829666230706143026","volume":"29","author":"R Ahmed","year":"2023","unstructured":"Ahmed R, Blum K, Thanos PK (2023) Epigenetic effects of psychoactive drugs. Curr Pharm Des 29:2124\u20132139","journal-title":"Curr Pharm Des"},{"key":"4569_CR32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2147\/PRBM.S445719","volume":"17","author":"SR Klein","year":"2024","unstructured":"Klein SR, Blum K, Gold MS, Thanos PK (2024) Chronic methylphenidate effects on brain gene expression: an exploratory review. Psychol Res Behav Manag 17:577\u2013592","journal-title":"Psychol Res Behav Manag"},{"key":"4569_CR33","first-page":"15","volume":"464","author":"BJ Morris","year":"1988","unstructured":"Morris BJ, Reimer S, Hollt V, Herz A (1988) Regulation of striatal prodynorphin mRNA levels by the raphe-striatal pathway. Brain Res 464:15\u201322","journal-title":"Brain Res"},{"key":"4569_CR34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0022-3565(25)39533-9","volume":"267","author":"RV Bhat","year":"1993","unstructured":"Bhat RV, Baraban JM (1993) Activation of transcription factor genes in striatum by cocaine: role of both serotonin and dopamine systems. J Pharmacol Exp Ther 267:496\u2013505","journal-title":"J Pharmacol Exp Ther"},{"key":"4569_CR35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0006-8993(96)00483-0","volume":"732","author":"PD Walker","year":"1996","unstructured":"Walker PD, Capodilupo JG, Wolf WA, Carlock LR (1996) Preprotachykinin and preproenkephalin mRNA expression within striatal subregions in response to altered serotonin transmission. Brain Res 732:25\u201335","journal-title":"Brain Res"},{"key":"4569_CR36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1124\/mol.51.5.755","volume":"51","author":"JJ Lucas","year":"1997","unstructured":"Lucas JJ, Segu L, Hen R (1997) 5-Hydroxytryptamine1B receptors modulate the effect of cocaine on c-fos expression: converging evidence using 5-hydroxytryptamine1B knockout mice and the 5-hydroxytryptamine1B\/1D antagonist GR127935. Mol Pharmacol 51:755\u2013763","journal-title":"Mol Pharmacol"},{"key":"4569_CR37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neuroscience.2004.10.030","volume":"131","author":"KA Horner","year":"2005","unstructured":"Horner KA, Adams DH, Hanson GR, Keefe KA (2005) Blockade of stimulant-induced preprodynorphin mRNA expression in the striatal matrix by serotonin depletion. Neuroscience 131:67\u201377","journal-title":"Neuroscience"},{"key":"4569_CR38","first-page":"177","volume":"264","author":"D Pan","year":"1994","unstructured":"Pan D, Gatley SJ, Dewey SL, Chen R, Alexoff DA, Ding YS, Fowler JS (1994) Binding of bromine-substituted analogs of methylphenidate to monoamine transporters. Eur J Neurosci 264:177\u2013182","journal-title":"Eur J Neurosci"},{"key":"4569_CR39","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1046\/j.1471-4159.1997.68052032.x","volume":"68","author":"R Kuczenski","year":"1997","unstructured":"Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032\u20132037","journal-title":"J Neurochem"},{"key":"4569_CR40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-3565(24)35066-9","volume":"291","author":"DS Segal","year":"1999","unstructured":"Segal DS, Kuczenski R (1999) Escalating dose-binge treatment with methylphenidate: role of serotonin in the emergent behavioral profile. J Pharmacol Exp Ther 291:19\u201330","journal-title":"J Pharmacol Exp Ther"},{"key":"4569_CR41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.tips.2005.12.003","volume":"27","author":"CP Muller","year":"2006","unstructured":"Muller CP, Huston JP (2006) Determining the region-specific contributions of 5-HT receptors to the psychostimulant effects of cocaine. Trends Pharmacol Sci 27:105\u2013112","journal-title":"Trends Pharmacol Sci"},{"key":"4569_CR42","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.neuropharm.2013.06.030","volume":"76","author":"KA Cunningham","year":"2014","unstructured":"Cunningham KA, Anastasio NC (2014) Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. Neuropharmacology 76:460\u2013478","journal-title":"Neuropharmacology"},{"key":"4569_CR43","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1177\/0269881117715598","volume":"31","author":"D Alter","year":"2017","unstructured":"Alter D, Beverley JA, Patel R, Bola\u00f1os-Guzm\u00e1n CA, Steiner H (2017) The 5-HT1B serotonin receptor regulates methylphenidate-induced gene expression in the striatum: Differential effects on immediate-early genes. J Psychopharmacol 31:1078\u20131087","journal-title":"J Psychopharmacol"},{"key":"4569_CR44","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0091-3057(00)00389-0","volume":"67","author":"N Castanon","year":"2000","unstructured":"Castanon N, Scearce-Levie K, Lucas JJ, Rocha B, Hen R (2000) Modulation of the effects of cocaine by 5-HT1B receptors: a comparison of knockouts and antagonists. Pharmacol Biochem Behav 67:559\u2013566","journal-title":"Pharmacol Biochem Behav"},{"key":"4569_CR45","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1460-9568.2010.07294.x","volume":"32","author":"V Van Waes","year":"2010","unstructured":"Van Waes V, Beverley J, Marinelli M, Steiner H (2010) Selective serotonin reuptake inhibitor antidepressants potentiate methylphenidate (Ritalin)-induced gene regulation in the adolescent striatum. Eur J Neurosci 32:435\u2013447","journal-title":"Eur J Neurosci"},{"key":"4569_CR46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.baga.2014.10.001","volume":"4","author":"JA Beverley","year":"2014","unstructured":"Beverley JA, Piekarski C, Van Waes V, Steiner H (2014) Potentiated gene regulation by methylphenidate plus fluoxetine treatment: long-term gene blunting (Zif268, Homer1a) and behavioral correlates. Basal Ganglia 4:109\u2013116","journal-title":"Basal Ganglia"},{"key":"4569_CR47","doi-asserted-by":"crossref","first-page":"100131","DOI":"10.1016\/j.addicn.2023.100131","volume":"9","author":"L Lamoureux","year":"2023","unstructured":"Lamoureux L, Beverley JA, Marinelli M, Steiner H (2023) Fluoxetine potentiates methylphenidate-induced behavioral responses: enhanced locomotion or stereotypies and facilitated acquisition of cocaine self-administration. Addict Neurosci 9:100131","journal-title":"Addict Neurosci"},{"key":"4569_CR48","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/s41386-023-01777-z","volume":"49","author":"L Lamoureux","year":"2024","unstructured":"Lamoureux L, Beverley J, Steiner H, Marinelli M (2024) Methylphenidate with or without fluoxetine triggers reinstatement of cocaine seeking behavior in rats. Neuropsychopharmacology 49:953\u2013960","journal-title":"Neuropsychopharmacology"},{"key":"4569_CR49","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1007\/s12035-021-02466-y","volume":"58","author":"C Moon","year":"2021","unstructured":"Moon C, Marion M, Thanos PK, Steiner H (2021) Fluoxetine potentiates oral methylphenidate-induced gene regulation in the rat striatum. Mol Neurobiol 58:4856\u20134870","journal-title":"Mol Neurobiol"},{"key":"4569_CR50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pbb.2015.01.005","volume":"131","author":"PK Thanos","year":"2015","unstructured":"Thanos PK, Robison LS, Steier J, Hwang YF, Cooper T, Swanson JM, Komatsu DE, Hadjiargyrou M, Volkow ND (2015) A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior. Pharmacol Biochem Behav 131:143\u2013153","journal-title":"Pharmacol Biochem Behav"},{"key":"4569_CR51","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2174\/1389201024666221028092342","volume":"24","author":"PK Thanos","year":"2023","unstructured":"Thanos PK, McCarthy M, Senior D, Watts S, Connor C, Hammond N, Blum K, Hadjiargyrou M, Komatsu D, Steiner H (2023) Combined chronic oral methylphenidate and fluoxetine treatment during adolescence: effects on behavior. Curr Pharm Biotechnol 24:1307\u20131314","journal-title":"Curr Pharm Biotechnol"},{"key":"4569_CR52","doi-asserted-by":"crossref","first-page":"100127","DOI":"10.1016\/j.addicn.2023.100127","volume":"8","author":"D Senior","year":"2023","unstructured":"Senior D, McCarthy M, Ahmed R, Klein S, Lee WX, Hadjiargyrou M, Komatsu D, Steiner H, Thanos PK (2023) Chronic oral methylphenidate plus fluoxetine treatment in adolescent rats increases cocaine self-administration. Addict Neurosci 8:100127","journal-title":"Addict Neurosci"},{"key":"4569_CR53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/B978-0-444-63425-2.00002-7","volume":"211","author":"H Steiner","year":"2014","unstructured":"Steiner H, Warren BL, Van Waes V, Bola\u00f1os-Guzm\u00e1n CA (2014) Life-long consequences of juvenile exposure to psychotropic drugs on brain and behavior. Prog Brain Res 211:13\u201330","journal-title":"Prog Brain Res"},{"key":"4569_CR54","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.npp.1301445","volume":"33","author":"J Borycz","year":"2008","unstructured":"Borycz J, Zapata A, Quiroz C, Volkow ND, Ferr\u00e9 S (2008) 5-HT(1B) receptor-mediated serotoninergic modulation of methylphenidate-induced locomotor activation in rats. Neuropsychopharmacology 33:619\u2013626","journal-title":"Neuropsychopharmacology"},{"key":"4569_CR55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neuropharm.2014.08.024","volume":"89","author":"V Van Waes","year":"2015","unstructured":"Van Waes V, Ehrlich S, Beverley JA, Steiner H (2015) Fluoxetine potentiation of methylphenidate-induced gene regulation in striatal output pathways: potential role for 5-HT1B receptor. Neuropharmacology 89:77\u201386","journal-title":"Neuropharmacology"},{"key":"4569_CR56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2005.01.018","volume":"510","author":"ZA Hughes","year":"2005","unstructured":"Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, Middlemiss DN, Dawson LA (2005) Neurochemical evaluation of the novel 5-HT1A receptor partial agonist\/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 510:49\u201357","journal-title":"Eur J Pharmacol"},{"key":"4569_CR57","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1358\/dot.2011.47.7.1622076","volume":"47","author":"RT Owen","year":"2011","unstructured":"Owen RT (2011) Vilazodone: a new treatment option for major depressive disorder. Drugs Today (Barc) 47:531\u2013537","journal-title":"Drugs Today (Barc)"},{"key":"4569_CR58","first-page":"28","volume":"37","author":"MP Cruz","year":"2012","unstructured":"Cruz MP (2012) Vilazodone HCl (Viibryd): a serotonin partial agonist and reuptake inhibitor for the treatment of major depressive disorder. Pharm Ther 37:28\u201331","journal-title":"Pharm Ther"},{"key":"4569_CR59","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/mds.100","volume":"33","author":"SM Meadows","year":"2018","unstructured":"Meadows SM, Conti MM, Gross L, Chambers NE, Avnor Y, Ostock CY, Lanza K, Bishop C (2018) Diverse serotonin actions of Vilazodone reduce L-3,4\u2010dihydroxyphenylalanine-induced dyskinesia in hemi\u2010parkinsonian rats. Mov Disord 33:1740\u20131749","journal-title":"Mov Disord"},{"key":"4569_CR60","doi-asserted-by":"crossref","DOI":"10.3390\/cells9102265","volume":"9","author":"F Altwal","year":"2020","unstructured":"Altwal F, Moon C, West AR, Steiner H (2020) The multimodal serotonergic agent vilazodone inhibits L-DOPA-induced gene regulation in striatal projection neurons and associated dyskinesia in an animal model of Parkinson\u2019s disease. Cells 9:2265","journal-title":"Cells"},{"key":"4569_CR61","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00213-022-06078-9","volume":"239","author":"S Smith","year":"2022","unstructured":"Smith S, Sergio J, Coyle M, Elder K, Centner A, Cohen S, Terry M, Lipari N, Glinski J, Wheelis E, Budrow C, Bishop C (2022) The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats. Psychopharmacology 239:2119\u20132132","journal-title":"Psychopharmacology"},{"key":"4569_CR62","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26195790","volume":"26","author":"F Altwal","year":"2021","unstructured":"Altwal F, Padovan-Neto FE, Ritger A, Steiner H, West AR (2021) Role of 5-HT1A receptor in vilazodone-mediated suppression of L-DOPA-induced dyskinesia and increased responsiveness to cortical input in striatal medium spiny neurons in an animal model of Parkinson\u2019s disease. Molecules 26:5790","journal-title":"Molecules"},{"key":"4569_CR63","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s12035-023-03688-y","volume":"61","author":"M Hrabak","year":"2024","unstructured":"Hrabak M, Moon C, Bola\u00f1os-Guzm\u00e1n CA, Steiner H (2024) Vilazodone, a selective serotonin reuptake inhibitor with diminished impact on methylphenidate-induced gene regulation in the striatum: role of 5-HT1A receptor. Mol Neurobiol 61:1907\u20131919","journal-title":"Mol Neurobiol"},{"key":"4569_CR64","doi-asserted-by":"crossref","unstructured":"Steiner H (2016) Psychostimulant-induced gene regulation in striatal circuits. In: Steiner H, Tseng KY (eds) Handbook of basal ganglia structure and function. Academic Press\/Elsevier, London, pp 639\u2013672","DOI":"10.1016\/B978-0-12-802206-1.00031-3"},{"key":"4569_CR65","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1046\/j.1460-9568.2003.02525.x","volume":"17","author":"I Willuhn","year":"2003","unstructured":"Willuhn I, Sun W, Steiner H (2003) Topography of cocaine-induced gene regulation in the rat striatum: relationship to cortical inputs and role of behavioural context. Eur J Neurosci 17:1053\u20131066","journal-title":"Eur J Neurosci"},{"key":"4569_CR66","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s12035-019-01739-x","volume":"57","author":"FE Padovan-Neto","year":"2020","unstructured":"Padovan-Neto FE, Patterson S, Voelkner NM, Altwal F, Beverley JA, West AR, Steiner H (2020) Selective regulation of 5-HT1B serotonin receptor expression in the striatum by dopamine depletion and repeated L-DOPA treatment: relationship to L-DOPA-induced dyskinesias. Mol Neurobiol 57:736\u2013751","journal-title":"Mol Neurobiol"},{"key":"4569_CR67","volume-title":"The rat brain in stereotaxic coordinates","author":"G Paxinos","year":"1998","unstructured":"Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic, New York"},{"key":"4569_CR68","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.neuroscience.2004.12.019","volume":"132","author":"M Yano","year":"2005","unstructured":"Yano M, Steiner H (2005) Methylphenidate (ritalin) induces Homer 1a and zif 268 expression in specific corticostriatal circuits. Neuroscience 132:855\u2013865","journal-title":"Neuroscience"},{"key":"4569_CR69","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1471-4159.2012.07852.x","volume":"122","author":"V Van Waes","year":"2012","unstructured":"Van Waes V, Carr B, Beverley JA, Steiner H (2012) Fluoxetine potentiation of methylphenidate-induced neuropeptide expression in the striatum occurs selectively in direct pathway (striatonigral) neurons. J Neurochem 122:1054\u20131064","journal-title":"J Neurochem"},{"key":"4569_CR70","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/adb.12067","volume":"19","author":"V Van Waes","year":"2014","unstructured":"Van Waes V, Vandrevala M, Beverley J, Steiner H (2014) Selective serotonin re-uptake inhibitors potentiate gene blunting induced by repeated methylphenidate treatment: Zif268 versus Homer1a. Addict Biol 19:986\u2013995","journal-title":"Addict Biol"},{"key":"4569_CR71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/35053570","volume":"2","author":"EJ Nestler","year":"2001","unstructured":"Nestler EJ (2001) Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2:119\u2013128","journal-title":"Nat Rev Neurosci"},{"key":"4569_CR72","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/17460441.2016.1160051","volume":"11","author":"ZT Sahli","year":"2016","unstructured":"Sahli ZT, Banerjee P, Tarazi FI (2016) The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder. Expert Opin Drug Discov 11:515\u2013523","journal-title":"Expert Opin Drug Discov"},{"key":"4569_CR73","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.tips.2004.12.007","volume":"26","author":"AN Samaha","year":"2005","unstructured":"Samaha AN, Robinson TE (2005) Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci 26:82\u201387","journal-title":"Trends Pharmacol Sci"},{"issue":"Suppl","key":"4569_CR74","doi-asserted-by":"crossref","first-page":"177S","DOI":"10.1093\/ajcn\/55.1.177s","volume":"55","author":"TT Yen","year":"1992","unstructured":"Yen TT, Fuller RW (1992) Preclinical pharmacology of fluoxetine, a serotonergic drug for weight loss. Am J Clin Nutr 55(Suppl):177S\u2013180S","journal-title":"Am J Clin Nutr"},{"key":"4569_CR75","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ajcn\/60.5.647","volume":"60","author":"DJ Goldstein","year":"1994","unstructured":"Goldstein DJ, Potvin JH (1994) Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 60:647\u2013657","journal-title":"Am J Clin Nutr"},{"key":"4569_CR76","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003495-200161010-00010","volume":"61","author":"SM Cheer","year":"2001","unstructured":"Cheer SM, Goa KL (2001) Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 61:81\u2013110","journal-title":"Drugs"},{"key":"4569_CR77","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/syn.890130408","volume":"13","author":"YL Hurd","year":"1993","unstructured":"Hurd YL, Herkenham M (1993) Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13:357\u2013369","journal-title":"Synapse"},{"key":"4569_CR78","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuropharm.2008.04.019","volume":"55","author":"PS Frankel","year":"2008","unstructured":"Frankel PS, Alburges ME, Bush L, Hanson GR, Kish SJ (2008) Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology 55:41\u201346","journal-title":"Neuropharmacology"},{"key":"4569_CR79","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.biopsych.2005.09.018","volume":"59","author":"EJ Nestler","year":"2006","unstructured":"Nestler EJ, Carlezon WAJ (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59:1151\u20131159","journal-title":"Biol Psychiatry"},{"key":"4569_CR80","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pharmthera.2007.06.011","volume":"116","author":"TS Shippenberg","year":"2007","unstructured":"Shippenberg TS, Zapata A, Chefer VI (2007) Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 116:306\u2013321","journal-title":"Pharmacol Ther"},{"key":"4569_CR81","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s002210050545","volume":"123","author":"H Steiner","year":"1998","unstructured":"Steiner H, Gerfen CR (1998) Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp Brain Res 123:60\u201376","journal-title":"Exp Brain Res"},{"key":"4569_CR82","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1176\/ajp.153.2.151","volume":"153","author":"SE Hyman","year":"1996","unstructured":"Hyman SE, Nestler EJ (1996) Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 153:151\u2013162","journal-title":"Am J Psychiatry"},{"key":"4569_CR83","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tins.2012.05.005","volume":"35","author":"ER Butelman","year":"2012","unstructured":"Butelman ER, Yuferov V, Kreek MJ (2012) \u03ba-opioid receptor\/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci 35:587\u2013596","journal-title":"Trends Neurosci"}],"updated-by":[{"DOI":"10.1007\/s12035-024-04621-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000}}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04569-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-024-04569-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04569-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T10:12:35Z","timestamp":1741083155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-024-04569-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["4569"],"URL":"https:\/\/doi.org\/10.1007\/s12035-024-04569-8","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: \"The reference citations were not properly placed in some areas and they have been corrected.\"","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12035-024-04621-7","URL":"https:\/\/doi.org\/10.1007\/s12035-024-04621-7","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures met the National Institutes of Health (NIH) guidelines for the care and use of laboratory animals (National Research Council, 2003) and were approved by the State University at Buffalo Institutional Animal Care and Use Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}